eHealth in Treatment of Gestational Diabetes (eMOMGDM)

The overall aim of the eMOM GDM-project is to develop and evaluate a novel system to clinical decision making and patient behavior change in treatment of GDM, combining diet, physical activity, sleep, heart rate (e.g. stress), and glucose monitoring within a single system (the eMOM GDM application), and linking the developed application tool for the normal health care system in a new way. In this second phase of the project, the effect of eMOM GDM application on maternal and neonatal outcomes will be evaluated in a randomized controlled study design. The follow-up study continues until 3 months postpartum.

Inclusion Criteria: * GDM diagnoses at 24-28 gestational weeks Exclusion Criteria: * type 1 or type 2 diabetes * use of medication that influences glucose metabolism (such as continuous therapy with oral corticosteroids or metformin) * multiple pregnancy * physical disability * current substance abuse * severe psychiatric disorder (that complicates participation to the study) * significant difficulty in cooperating (e.g. inadequate Finnish language skills)